{"entity":{"id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","aka":[],"tldr":"A phase 1/2 trial of THEO-260 in ovarian cancer, run by Theolytics Limited, now recruiting.","summary":"Trial of THEO-260 in Ovarian Cancer Patients is a phase 1/2 interventional study registered as NCT06618235 by Theolytics Limited, with 44 participants planned, started 2024-09-24 and due to reach its primary completion in 2028-06. Interventions recorded: THEO-260.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06618235","url":"https://clinicaltrials.gov/study/NCT06618235"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06618235","phase":"1/2","setting":"A Phase I/IIa, Open-label, Dose Finding, Safety, Tolerability and Exploratory Trial of THEO-260 in Patients With High Grade Serous or Endometrioid Ovarian Cancer","sponsor":"Theolytics Limited","enrolled":44,"outcomes":[]},"route":"/trials/nct06618235/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/"}]}}